Overview

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Status:
Completed

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.

Phase:

Phase 4

Details

Lead Sponsor:

University of Chicago

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Alemtuzumab